{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-046259","form_type":"8-K","ticker":"ARVN","cik":"0001655759","company_name":"ARVINAS, INC.","filed_at":"2025-10-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.059596+00:00","generated_at":"2026-05-17T02:20:48.895087+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Arvinas ARV-806 preclinical data: >90% KRAS G12D degradation for 7 days in xenograft models","bullets":["ARV-806 degraded KRAS G12D with picomolar potency across pancreatic, colorectal, and lung cancer cell lines without affecting wild-type RAS.","Compared with clinical-stage inhibitors and another G12D degrader, ARV-806 showed >25-fold greater antiproliferative potency and >40-fold higher degradation potency.","Single dose degraded >90% of KRAS G12D for 7 days in colorectal xenograft, with c-MYC suppression and BIM induction for ≥5 days.","Achieved ≥30% tumor volume reductions in pancreatic, colorectal CDX and lung PDX models at low doses.","Phase 1 trial in KRAS G12D-mutated advanced solid tumors (NCT07023731) ongoing; orally bioavailable pan-KRAS degraders also identified."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-046259","json":"https://secwatch.observer/filing/0001628280-25-046259.json","markdown":"https://secwatch.observer/filing/0001628280-25-046259.md","text":"https://secwatch.observer/filing/0001628280-25-046259.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1655759/000162828025046259/0001628280-25-046259-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1655759/000162828025046259/arvn-20251024.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:20:48.895087+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}